Molecular biomarkers to guide precision medicine in localized prostate cancer by Smits, M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177633
 
 
 
Please be advised that this information was generated on 2020-09-08 and may be subject to
change.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iero20
Expert Review of Molecular Diagnostics
ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: https://www.tandfonline.com/loi/iero20
Molecular biomarkers to guide precision medicine
in localized prostate cancer
Minke Smits, Niven Mehra, Michiel Sedelaar, Winald Gerritsen & Jack A.
Schalken
To cite this article: Minke Smits, Niven Mehra, Michiel Sedelaar, Winald Gerritsen & Jack A.
Schalken (2017) Molecular biomarkers to guide precision medicine in localized prostate cancer,
Expert Review of Molecular Diagnostics, 17:8, 791-804, DOI: 10.1080/14737159.2017.1345627
To link to this article:  https://doi.org/10.1080/14737159.2017.1345627
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Accepted author version posted online: 21
Jun 2017.
Published online: 05 Jul 2017.
Submit your article to this journal 
Article views: 1365
View related articles 
View Crossmark data
Citing articles: 7 View citing articles 
REVIEW
Molecular biomarkers to guide precision medicine in localized prostate cancer
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ABSTRACT
Introduction: Major advances through tumor profiling technologies, that include next-generation
sequencing, epigenetic, proteomic and transcriptomic methods, have been made in primary prostate
cancer, providing novel biomarkers that may guide precision medicine in the near future.
Areas covered: The authors provided an overview of novel molecular biomarkers in tissue, blood and
urine that may be used as clinical tools to assess prognosis, improve selection criteria for active
surveillance programs, and detect disease relapse early in localized prostate cancer.
Expert commentary: Active surveillance (AS) in localized prostate cancer is an accepted strategy in
patients with very low-risk prostate cancer. Many more patients may benefit from watchful waiting, and
include patients of higher clinical stage and grade, however selection criteria have to be optimized and
early recognition of transformation from localized to lethal disease has to be improved by addition of
molecular biomarkers. The role of non-invasive biomarkers is challenging the need for repeat biopsies,
commonly performed at 1 and 4 years in men under AS programs.
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1. Introduction
Prostate cancer (PCa) is the most common malignancy in men
[1–3] and a major cause of male cancer deaths [1]. Prostate-
specific antigen (PSA) is still the only available biomarker to aid
the early diagnosis of PCa, but it leads to overdiagnosis and
overtreatment due to its low specificity and its inability in
predicting aggressive disease [2,4,5]. Insight in the molecular
changes involving key signaling pathways in primary PCa has
undergone major advances through the rapid innovation and
implementation of tumor profiling technologies that include
next-generation sequencing (NGS) and epigenetic-, proteomic-
, and transcriptomic methods. Systematic analyses from these
comprehensive studies have provided an understanding of the
unique molecular subclasses and of the heterogeneity seen in
primary PCa. We provide a comprehensive overview of the
most promising translational research on biomarkers that may
guide precision medicine of primary PCa in the near future.
These molecular aberrations include recurrent gene fusions,
genetic and epigenetic alterations, aberrant protein, and
(micro)RNA expression and can be detected in virtually all
cellular compartments such as tissue, in urine, and in the per-
ipheral blood. Molecular biomarkers are being incorporated
with current selection criteria to identify patients with low-risk
localized PCa (pT1/2 PCa, Gleason 6, three or fewer positive
biopsies, and a PSA <10 ng/mL) that are either misclassified or
have molecular features of an aggressive phenotype. In this
review, we comment on the implementation of novel molecular
biomarkers to aid clinicians in the selection of newly diagnosed
hormone-sensitive patients for radical treatment studies vs.
watchful waiting and the monitoring of patients during surveil-
lance programs following radical surgical or radiotherapeutic
treatment of the prostate. For biomarkers in the early diagnosis
setting, we refer to our colleagues [5,6].
2. ETS gene fusions; TMPRSS2–ERG
The most common alterations in PCa genomes are recurrent
somatic gene fusions with members of the ETS family of
transcription factors, detected in about half of all Caucasian
patients with primary PCa [7]. These nonrandom fusions are
clonal and arise from site-specific double-stranded breaks near
androgen receptor (AR)-binding sites, presumably due to per-
sistent activated AR signaling, genotoxic stress, and recruit-
ment of specific stress-induced enzymatic processes [8]. A
typical fusion partner arises from the androgen-regulated
transmembrane serine protease isoform 2 (TMPRSS2) and
ERG. ERG overexpression is seen in at least half of the patients
with PCa [5,9] with other fusion partners including other
family members such as ETV1, ETV5, and FLI1 [10,11]. Fusion
genes can be detected by whole-genome sequencing (WGS),
real-time polymerase chain reaction (RT-PCR), targeted
sequencing (deletion of 21q22.2–22.3 near TMPRSS2), fluores-
cent in situ hybridization (FISH), and immunohistochemistry
(IHC). The detection shows high specificity as a diagnostic tool,
but their use in the prognostication and during active surveil-
lance (AS) of primary PCa is currently debated [2,4,5].
2.1. ETS gene fusions as prognostic biomarker
Petterson et al. prospectively investigated 1180 patients with
PCa recruited to the Physicians Health Study and the Health
Professionals Follow-Up Study, who underwent a radical pros-
tatectomy (RP). During a mean follow-up of 12.6 years, 266
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men experienced biochemical relapse (BCR). Forty-nine per-
cent of all men had tumors overexpressing ERG by IHC. They
found no association between ERG overexpression and BCR,
lethal progression (including metastases and PCa-specific
death), or overall mortality. This group also performed a
meta-analysis comprising 10,803 patients with PCa and con-
firmed findings from their own cohort; no association was
found between ERG overexpression and lethal progression of
PCa, although different tissue sampling methods and assays
were used between the studies [9]. TMPRSS2–ERG expression
was also of no prognostic significance in several other studies
[12,13]. FitzGerald et al. did not find any relationship of pre-
sence of the TMPRSS2–ERG gene fusion using FISH assay with
PCa-specific mortality, nor was there a significant worse dis-
ease-specific survival (DSS) in patients with multiple copies of
the fusion [13]. Kulda et al. investigated the association
between TMPRSS2–ERG expression and disease-free survival
in 108 patients with PCa by RT-PCR and found a significantly
shorter DSS in patients with high RNA expression compared to
patients with mere presence, showing most promise as a
prognostic biomarker in those with preoperative PSA levels
>10 ng/mL [14]. Font-Tello et al. published similar results in a
smaller cohort [15]. Berg et al. prospectively investigated 265
patients with low-risk PCa, confirmed by biopsy, who were
under AS and followed for a median 4.1 years. In competing
risk models, patients with ERG overexpression at diagnosis
showed a significantly higher incidence of overall AS progres-
sion, PSA progression, and histopathologic progression. After
2 years, overall AS progression was 21.7% vs. 58.6% in ERG-
negative and ERG-positive patients, respectively [16]. Hagglof
et al. and Demichelis et al. both retrospectively investigated a
cohort of patients with PCa who were managed by watchful
waiting. Here, ERG overexpression was significantly associated
with a shorter DSS [17,18]. When correcting for Gleason score
(GS), as higher ERG expression is found in GS >7 PCa, no
significant association remained [18].
TMPRSS2–ERG fusion is a common genetic event in PCa,
but due to conflicting results between studies, we see no
direct implementation of fusion status or copy number as a
prognostic biomarker in PCa.
3. Somatic copy number aberration
Exploration of the primary PCa genome identified frequent
molecular abnormalities involving chromosomal arm-level
DNA somatic copy number aberration (SCNA). Frequent geno-
mic losses are seen in chromosomes 6p, 8p, 13q, 16, and 18q,
involving tumor suppressor genes such as phosphatase and
tensin homolog (PTEN), retinoblastoma protein (RB1), TP53,
cyclin-dependent kinase inhibitor 1B (CDKN1B or p27), CHD1,
mitogen-activated protein kinase kinase kinase 1 (MAP3K1),
and Fanconi anemia, and complementation group D2
(FANCD2). Genomic gains are frequently seen of 2p, 7, 8q,
and 11 and include oncogenes cyclin D1 (CCND1), myelocyto-
matosis viral oncogene homolog (MYC), and fibroblast growth
factor receptor 1 (FGFR1) [3,19,20]. The prognostic role of
SCNA may be analyzed by different approaches, investigating
either specific genetic gains or deletions, or by analyzing the
overall burden of SCNA [21]. SCNA burden represents the level
of copy number gains and losses across the genome in a
tumor [22], associating strongly with the five prognostic
grade groupings (PGGs) [7].
3.1. SCNA as prognostic biomarker
Research by Taylor et al. identified two notable clusters of
primary tumors based on the number of genome-wide
SCNA. The most cluster with SCNA had an extremely favorable
prognosis, in relation to time to BCR, compared to the cluster
with substantial/high SCNA [19]. Following up on these initial
results, Hieronymus et al. analyzed genome-wide SCNAs in
patients who underwent an RP; they described an average
SCNA burden of 5% in patients with primary PCa, with a
wide range between 0.1% and >50%. SCNA burden associated
with BCR in multivariate models, when correcting for pretreat-
ment PSA and Gleason score, importantly also remaining an
independent predictor in patients with intermediate-risk PCa
(GS 3 + 4 and GS 4 + 3) [22]. A study by Liu et al. evaluated 125
patients in an initial discovery cohort that underwent RP for
specific SCNA in their tumors by array comparative genomic
hybridization (aCGH); 20 specific regions were identified with
SCNA; of these, 7 associated with DSS, with PTEN loss and MYC
gain remaining significantly associated with a higher risk of
DSS. Results were confirmed in 333 tumors from 3 additional
distinct patient cohorts [23].
3.2. PI3K/AKT pathway (PTEN)
The phosphatidylinositol-3-kinase (PI3K)/Akt pathway plays a
fundamental role as a regulator of PCa cellular proliferation
and survival [24]. Several components regulating the PI3K
pathway activity are altered in primary PCa, most commonly
PTEN, and less frequent PIK3CA (encoding p110α subunit) and
Akt [3]. PTEN is a tumor suppressor gene located on chromo-
some 10 with multiple functions, one of which is regulating
PI3K activity through dephosphorylating second messenger
PIP3 into PIP2, and thereby suppressing Akt and downstream
pathway activation [24]. PTEN functional loss is one of the
most common genetic events occurring in human cancer;
mutation, 10q copy loss, or aberrant posttranscriptional reg-
ulation lead to nonfunctional or lack of PTEN expression in
approximately half of patients with primary PCa [21,25–27]
3.2.1. PTEN as prognostic biomarker
Liu et al. investigated SCNAs in a discovery cohort of 125
patients with PCa, who underwent RP and found 20 significant
SCNAs, of which 15 were chromosomal deletions and 5 were
gains or amplification. PTEN loss was significantly associated
with disease-specific mortality in multivariate analysis, with an
odds ratio (OR) of 7.31. This relationship was confirmed in two
other independent comparable patient cohorts [23]. Multiple
retrospective studies confirmed the significance of PTEN loss
in prognosis [22,23,26,28–30]. In a prospective study of 1044
patients with PCa, Ahearn et al. identified an association of
PTEN IHC loss with lethal progression, defined as metastases
to bone or organs and PCa death, but only in patients without
ERG overexpression. Complete loss predicted a significantly
higher risk for lethal progression than heterogeneous or no
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 793
loss [31]. Lahdensuo et al. showed in molecular unselected
PCa patients that PTEN loss alone could not predict overall
survival (OS), but could predict a shorter PCa-specific survival
in patients without ERG overexpression. Patients with unde-
tectable PTEN protein by IHC had a greater risk of PCa-related
death compared to those with low, heterogeneous, or normal
staining [26]. In 326 patients with PCa, who underwent RP,
PTEN loss assessed by FISH was seen in 15%. These patients
also had a shorter progression-free survival (PFS) than patients
with detectable PTEN expression. In multivariate analysis,
PTEN expression had a borderline significant (p = 0.052) asso-
ciation with PFS [32]. Hieronymus assessed SCNA burden and
specific genomic alterations using low-pass WGS and high-
resolution aCGH. PTEN was the only alteration associated
with disease relapse. The literature to date shows that changes
in PTEN/PI3K signaling are associated with aggressive PCa,
albeit that there are still technical analytical issues to resolve
before implementing this in routine clinical practice.
3.3. MYC
Chromosome 8q24 harbors the MYC gene, an oncogene
amplified in approximately 8% of primary PCa [33].
Clustering of 333 primary PCa revealed that cluster 6, dis-
tinguished by substantial SCNA, was strongly enriched for
MYC [3]. MYC is a family member of MYCL and MYCN, and
these genes appear differentially expressed per clinical
stage. MYCL can be detected in primary PCa, described by
Boutros et al. [34], where a novel recurrent amplification of
MYCL gain was reported, and was independent of gains in
MYC. In their cohort, MYCL gain was associated with TP53
loss, of which the functional relevance is not fully under-
stood, but suggest a unique gene expression profile of PCa
and may be of prognostic utility [34]. MYCN is only found in
aggressive castration-resistant PCa (CRPC) and mainly in
neuroendocrine PCa, together with TP53/RB1 loss-of-func-
tion mutation or deletion. MYC promotes cell growth
through direct binding of ribosomal DNA and activation of
ribosomal RNA. MYC and MYCN regulate enhancer of zeste
homolog (EZH2), which is linked to PCa progression. NKX3.1
is a prostate-specific transcription factor and competes with
MYC target genes. In PCa, loss of NKX3.1 can lead to loss of
suppression of MYC activity [33].
3.3.1. MYC as a prognostic biomarker
In the same study by Liu et al. as described earlier, MYC gain
was also significantly correlated with disease-specific mortality
in multivariate analysis. Particularly, patients with tumors har-
boring both PTEN loss and MYC gain had a marked increase in
the risk of disease-specific death. The association of MYC gain
alone and the combination of both alterations with risk of
death was confirmed in two other cohorts [23]. In a prospec-
tively designed study with 126 patients with intermediate-risk
PCa, who underwent radical radiotherapy, presence of PTEN
and MYC alterations was significantly associated with an
increased percentage SCNA. Patients with MYC gain, or both
MYC gain and PTEN loss, had a significantly higher risk of BCR.
However, PTEN loss could not predict BCR [35]. This is in con-
trast to the study by Hieronymus et al. described earlier, where
there was a significant association between BCR and PTEN copy
number loss, without any association for MYC gain [22].
4. Inter- and intrachromosomal rearrangement;
chromoplexy and chromothripsis
Whereas tumors can be driven by recurrent point mutations in
oncogenes, structural alterations in the PCa genome appear to
be the primary driver of PCa progression. WGS studies have
detected complex genomic chained rearrangements, with
balanced breaks and joins that can span multiple chromo-
somes, generating chimeric chromosomes, a process termed
chromoplexy (from the Greek word for weave or braid)
[36,37]. Chromoplexy generates copy-neutral rearrangements
and tends to occur near ‘open’ chromatin in ETS-positive
tumors, but may also to occur in ETS-negative PCa [38].
Another phenomenon that leads to structural rearrangement
is chromothripsis or chromosome shattering. Chromothripsis
also displays random breakage and fusion, driven by focal
genomic instability at the level of DNA double-strand breaks
(DSBs), occurring within one or two chromosomes only and
leading to the formation of hundreds of clustered rearrange-
ments [39,40]. Both chromoplexy and chromothripsis can there-
fore dysregulate multiple genes in parallel to drive prostate
tumorigenesis [41].
4.1. The prognostic value of chromothripsis
In a recent study by Fraser et al., 284 patients with localized
PCa (GS 3 + 3, 3 + 4, or 4 + 3) were included to investigate its
genetic drivers, with WGS performed in 130 tissue and
matched blood samples. Chromothripsis was found in 20%
of these tumors using ShatterProof, a software tool for detect-
ing and quantifying chromothryptic events introduced by
Govind et al. [42]. Overall SCNA burden was only modestly
increased in chromothriptic tumors; however, risk of BCR was
not correlated to the presence of chromothripsis [39]. Another
prospective study included patients with different GS and
observed an incidence of chromothripsis of 30%.
Surprisingly, chromothripsis was mainly observed in the
group of patients with GS 6 [43]. To date, correlative studies
on chromothripsis and outcome in hormone-sensitive prostate
cancer (HSPC) indicate that presence of chromothripsis does
not predict aggressiveness of disease. Specific information on
structural events is required to obtain information about its
prognostic and predictive role.
5. Chromatin remodeling
Structural rearrangements may arise from focal DNA DSBs at
transcriptional hubs, such as areas of AR transcriptional activ-
ity, resulting in rearrangements of the androgen-regulated
TMPRSS2 gene and ETS fusion genes, and increased presence
of chromoplexy or chromothripsis in general. Also, the result
of change in chromatin architecture may contribute to a
chromosomal instable phenotype. Seven different molecular
subtypes have been described by the Cancer Genome Atlas
Research Network, of which one assigned subgroup of ETS-
negative cancers with Speckle-Type-POZ Protein (SPOP)
794 M. SMITS ET AL.
mutation and recurrent somatic deletions at the 5q21 locus
containing the chromodomain helicase DNA-binding protein 1
(CHD1) [3,44]. SPOP functions as the substrate recognition
component of an E3 ubiquitin ligase and is a key regulator
of DSB repair. CHD1 is a chromatin-remodeling factor involved
in the regulation of gene transcription through interaction
with open chromatin and orchestrates DSB repair by complex-
ing with components involved in both homologous recombi-
nation and nonhomologous end-joining. CHD1-loss or SPOP-
mutant/CHD1-loss subtype is characterized by increased geno-
mic instability and chromosomal rearrangements [39,45]. In a
study by Barbieri et al., the exomes of 112 prostate tumor
samples and matched normal tissue samples were sequenced.
All these patients were treatment naive, mainly with GS ≤7,
and an SPOP mutation was found by FISH in 13%. In additional
cohorts comprising over 300 primary cancers, SPOP mutation
was found in 6–13% and in 14% of patients with metastatic
PCa [44]. Other studies confirmed this prevalence [46,47]. The
prognostic importance of the ETS-fusion-negative SPOP-
mutated/CHD1 loss subgroup was investigated in several
studies.
5.1. Prognostic value of SPOP mutation/CHD1 loss
In a study by Boysen et al., it was shown that the SPOP
mutation reduces efficient DNA DSB repair and that it is
associated with genomic instability in samples of patients
with localized PCa. SPOP-mutated tumors were significantly
associated with a higher SCNA burden. In this study, the
associated deletion associated with CHD1 loss was confirmed
to be enriched in SPOP-mutated tumors [45].
In an international multicenter study of 720 mainly GS
≤7 patients, 8.1% of the samples had a detectable SPOP
mutation and were significantly enriched for CHD1 dele-
tions (57.9% vs. 15%). There was no significant association
between the presence of an SPOP mutation in patients
treated by RP and BCR or survival [46]. Other studies con-
firmed the presence of CHD1 deletions but could not con-
firm its prognostic relevance [23,47]. In contrast, another
study with 265 samples of patients with almost all loca-
lized PCa, who underwent an RP and were followed for at
least 5 years, identified a prognostic role for SPOP. Here,
the presence of SPOP mutations was associated with a
worse biochemical PFS with multivariate testing [48]. A
worse prognostic outcome in patients with a CHD1 dele-
tion was found in a study by Taylor et al., where CHD1
deletion was significantly associated with BCR, also con-
firmed by Rodrigues et al. [19,49]. Considering the recent
hypothesis that CHD1-deleted tumors might be sensitive
for Poly (ADP-ribose) Polymeras (PARP) inhibitors due to
aberrant DSB repair [45,50], CHD1 may provide a valuable
biomarker with both prognostic and predictive
characteristics.
6. Oncotype DX Genomic Prostate Score
The Oncotype DX Genomic Prostate Score (GPS) is a multigene
expression assay based on a RT-PCR platform, which assesses
the RNA expression of 12 cancer-related genes (and 5
reference genes) representing four biological pathways with
a role in prostate tumorigenesis: androgen signaling, prolifera-
tion, cellular organization, and stromal response [2,51]. Klein
et al. developed this assay and identified 12 genes with inde-
pendent molecular information in primary tissue from two
separate cohorts and validated the test in a third cohort.
They found in uni- and multivariate analyses a significant
association between the GPS and high-risk disease [52].
6.1. Prognostic value of Oncotype DX genomic prostate
score
One prospective study investigated the prognostic role of GPS
in BCR-free survival and time to clinical progression. In this
study, a cohort of 431 patients with very low-, low-, and
intermediate-risk PCa, who underwent RP, was evaluated.
There was a significant association between GPS at diagnosis
and time to BCR, in both uni- and multivariate analyses. With a
follow-up of 5.2 years, the study was underpowered to report
on metastases-free survival [51].
7. Decipher test
The Decipher (GC) test is a test evaluating the expression
levels of 22 RNA biomarkers, including genes involved in the
development and progression of PCa but also noncoding RNA
sequences on tumor tissue [53].
7.1. Prognostic value of Decipher
Decipher was first developed by Erho et al., who included
patients with rising PSA after RP as a training cohort together
with patients with early metastasis after RP as controls in a
nested case-control study. A total of 22 RNA biomarkers were
selected using a transcriptome-wide approach from the 545
samples to predict early clinical metastasis (35% of patients
developed metastases over a median of 16.9 months).
Decipher score was able to distinguish between those that
developed metastases from those who did not. Patients with a
low Decipher score had a median PCa-specific survival of
6.9 years compared to 2.9 years in patients with high scores.
OS after metastasis was also significantly better in patients
with low Decipher scores [53].
Different studies have shown a significant association
between the Decipher score and BCR-free survival, clinical
progression, and PCa-specific mortality [54–57]. All
these studies were exploratory studies performed in
retrospect.
8. Cell-cycle progression score (Prolaris)
The expression levels of cell-cycle progression (CCP) genes
reflect fundamental aspects of tumor biology. To investigate
the probability of the use of CCP genes in their ability to predict
disease outcome, Cuzick et al. selected a set of 46 genes; 31 CCP
genes presumably reflecting the fraction of tumor cells actively
dividing and 15 housekeeping genes. They found in two large
retrospective cohorts, 1 of the 410 patients following RP, and 1
of the 337 patients managed conservatively, a significant
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association between the CCP score (also known as Prolaris) and
BCR and DSS, respectively [58].
8.1. Prognostic value of Prolaris
In 349 patients with localized PCa treated with androgen depriva-
tion therapy (ADT), mainly comprising the same cohort of patients
from the seminal publication of Cuzick et al., the Prolaris test
appeared a stronger predictor of OS compared to GS and PSA [59].
Other retrospective studies have confirmed the prognostic
value of Prolaris [60–62]; however, in a recent retrospective
study with a small cohort of newly diagnosed patients with
PCa that underwent RP, Prolaris was of significance in the
prediction of BCR as well, but only in univariate analysis;
however, results from the multivariate analysis should be
addressed with caution due to low events (n = 15) in a small
cohort of 52 patients. When staged according to the risk
classification proposed by the European Association of
Urology, 7 high-risk and 13 intermediate-risk PCa patients of
a total of 52 patients were classified differently by Prolaris [63].
9. AR alterations
Androgen signaling plays a pivotal role in HSPC, with testi-
cular, adrenal, and intratumoral androgens driving PCa
growth. AR alterations, such as AR mutation, amplification,
and genomic structural rearrangements, are very infrequent
in hormone-naive HSPC, but the second most frequent
aberration (aside from ERG fusion) in the CRPC state. First
line of systemic therapy for hormone-naive PCa patients is
ADT, decreasing androgen concentrations and diminishing
AR signaling. In patients harboring micrometastatic cancer,
the disease invariable recurs as CRPC with detectable AR
alterations associating with ADT resistance [64]. Other
alterations frequently occurring are mutation of FOXA1
and SPOP and gain of NCOA2, which increase AR-driven
transcription in human PCa [19,20,64]. In addition, diverse
AR variant species have recently been described, with cer-
tain variant species lacking the ligand-binding domain and
making them constitutively active; these AR splice variants
(AR-Vs) drive PCa growth in a ligand-independent way [3].
These AR variants can arise from AR genomic structural
rearrangement or by posttranscriptional regulation due to
alternative splicing [65]. AR-Vs are well studied in CRPC,
with only limited data on AR-V expression in treatment-
naive HSPC [3]. One such AR-V is AR-V7 that lacks exon 2
and 3 encoding the DBD and is the most commonly
expressed splice variant in the CRPC state. A recent publica-
tion by Saylor et al. only identified the presence of AR-V7 in
one patient with GS 9, out of a total of 30 patients with
HSPC using RNA in situ hybridization [66]. This is in contrast
with data from the The Cancer Genome Atlas (TCGA) data
set of primary PCa, where RNA sequencing commonly iden-
tified several AR-Vs at low levels in primary tumors (in 50%
of cases) and in a few cases even in benign prostate tissue
[3]. The utility in the prognostication of AR-Vs in primary
disease and in AS has sparsely been reported on.
9.1. Prognostic value of AR
In 2004, Li et al. investigated in retrospect by IHC AR expres-
sion in 640 patients with PCa who underwent RP. In line with
AR signaling driving HSPC progression, increased AR expres-
sion was significantly associated with a reduced BCR-free sur-
vival in uni- and multivariate analyses [67].
Rosner et al. retrospectively compared AR gene expression
levels using qRT-PCR between patients with PCa who under-
went RP and those with benign prostate hyperplasia (BPH).
Higher RNA expression was significantly associated with BCR
in uni- and multivariate analyses [68].
Recently, Welti et al. retrospectively identified 37 patients
with HSPC, who progressed to CRPC. AR-V7 expression was
investigated by IHC in both HSPC and CRPC tissues. Most
patients showed lower AR-V7 expression in HSPC compared
to CRPC tissue, although some HSPC patients revealed the
reverse trend. OS was significantly shorter in CRPC patients
with higher AR-V7 expression from time of CRPC biopsy; how-
ever, OS from time of diagnosis was not presented in this
small study [69].
In a retrospective study, containing 82 patients with HSPC
who underwent RP, higher expression of AR-V7 was signifi-
cantly associated with a worse BCR, with no relationship found
for AR-V1 [70]. In contrast, Zhao et al. retrospectively investi-
gated 53 patients with low- and intermediate-risk PCa and did
not find any association between AR-V7 or AR-V1 expression
and BCR [71]. The very good analytical sensitivity of PCA-based
methods can reveal specific AR-V7 transcripts that are not
found at the protein level, which in part may explain the
discrepancies in the studies.
10. DNA damage repair deficiency
Defects in DNA damage repair (DDR) pathways are a hallmark
of human cancer with somatic events seen in up to 20% of
primary PCa; these include homo- and heterozygous deletions
and loss-of-function mutations in genes involved in single-
strand break repair (including base-excision repair, nucleo-
tide-excision repair, and mismatch-repair) and DSB repair
(homologous recombination and nonhomologous end-join-
ing). The most commonly altered DDR genes are those
involved in homologous recombination, which require the
sister chromatid as template and repair DNA error-free, and
include BRCA1, BRCA2, CDK12, ATM, FANCD2, and CHEK2
among others [3,64,72,73]. Germ line defects are found around
in 4.6% patients with localized high-risk disease, but recent
findings suggest rates around 12% in CRPC, significantly
exceeded the prevalence found in localized PCa from data of
the TCGA data set [3,73–75]; this implies enrichment of DDR
deficiency during the transition towards a metastatic castra-
tion-resistant state. In metastatic castration-resistant prostate
cancer (mCRPC), these molecular selected patients benefit
from certain therapies, like PARP inhibitors, and probably
from platinum-based chemotherapy [64,72,73]. Although less
common, these defects in primary PCa also are both of prog-
nostic and predictive utility [3,74,75]. Castro et al. retrospec-
tively evaluated the prognostic value of BRCA1 and BRCA2 in
primary PCa patients; patients with BRCA1/2 mutations had
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more aggressive disease, associating with high GS ≥8, high
clinicopathological stage and presence of nodal metastases at
diagnosis. BRCA1/2 mutation carriers had twice as common
poorly differentiated PCa compared to noncarriers. In a sub-
group analysis of patients with localized PCa, the 5-year DSS
and metastasis-free survival were significantly better in non-
carriers compared to patients with BRCA1/2 mutations. There
was no difference in outcome between patients with BRCA1
and BRCA2 mutation status [74]. A recently presented abstract
by Kolinsky et al. confirms that patients with germ line or
somatic defects in DDR genes present with high-risk PCa and
metastatic disease at diagnosis [76]; in particular, those with
BRCA2 aberrations had a significantly worse OS from diagnosis
than those patients with other affected DNA repair genes
(including ATM, BRCA1, CDK12, HDAC2, CHEK2, FANCA,
PALB2, and BLM). Patients with BRCA2 aberrations had poorer
response rates to AR targeting therapy compared to response
data from the preregistration phase III trials. Whether DDR
deficiency in the primary setting, and in particular BRCA2
loss-of-function/deletion, associates with poorer response to
ADT has not been answered in a prospective trial.
11. Epigenetic alterations
Epigenetic alterations are heritable traits (phenotypes) that
modulate gene expression and cannot be explained by changes
in the underlying DNA sequence. Epigenetic changes include 5'-
C-phosphate-G-3' (CpG) methylation, histone modification,
gene imprinting, and microRNAs (miRs) [77]. These alterations
may target the whole genome, including silencing of tumor-
suppressor genes and genes promoting genomic instability,
DNA repair, cell-cycle control, and apoptosis [77–79].
11.1. DNA hypermethylation
Promoter-hypermethylation of tumor-suppressor genes can
be identified in PCa patients in tissue or in circulating cell-
free DNA [79]. A systematic review by Chao et al. found
glutathione S-transferase pi 1 (GSTP1) and adenomatous poly-
posis coli (APC) to be the most evaluated hypermethylated
genes in PCa [79]. In multivariate analysis, high-level APC
methylation associated with a worse DSS. Biochemical recur-
rence was detected in 45% of the patients during the follow-
up with high-level methylation of APC and clinical stage sig-
nificantly associated with BCR [80]. In a study by Rosenbaum
et al., quantitative methylation-specific PCR was performed to
analyze six gene promoters in a homogenous group of
patients with GS 3 + 4 = 7, who underwent RP, of which
50% of patients developed recurrent disease during the fol-
low-up period. Hypermethylation of APC was significantly
associated with a shorter time to progression [81]. The prog-
nostic value of hypermethylated APC has been confirmed in
several other studies [82,83]. The prognostic value of hyper-
methylated GSTP1 is less clear, with conflicting results
between studies for OS [80,82] and for BCR [80,81,83,84].
Hypermethylation of (promoter region of) genes driving PCa
progression can readily be detected in tissue or in liquid
biopsies, with early studies showing promise as a prognostic
biomarker in PCa; further research is still required to
determine which hypermethylated gene tests should be
developed and incorporated in prospective biomarker trials
of primary PCa to guide treatment decision choices.
11.2. Cell-free microRNAs
MicroRNAs (miRs) are short noncoding single-stranded RNAs,
containing up to 24 nucleotides, that control gene expression
at the posttranscriptional level [85]. Differential miR expression
profiles are found in cancer and precursor lesions, through
genetic, epigenetic, and transcriptional mechanisms, and may
drive the development and progression of cancer by control-
ling expression of oncogenes and tumor suppressor genes
[86,87]. Whether deregulation leads to higher or lower levels
of miRs depends on their target function [87]. For example,
miR-21, miR-19b, miR-23b, miR-26a, miR-92a, and miR-221/222
can promote tumor growth by targeting the PI3K pathway
and PTEN, causing activation of Akt [85,88,89].
MiRs can be detected in virtually all bodily fluids and
tissues by qRT-PCR, and NGS panels have been developed to
detect miR profiles of significance in PCa [90] and are promis-
ing biomarkers in primary PCa and AS.
11.2.1. Prognostic value of MiRs
Melbo-Jorgensen et al. investigated 535 patients with PCa,
who underwent RP and profiled 1435 miRs in a subgroup of
30 patients, of which 14 experienced rapid BCR and 16 did
not. Of a total of 1435 miRs quantified, 7 miRs from the top 50
miRs with strongest discriminatory characteristic were further
validated by RT-PCR. In this validation, only miR-21 remained
significantly upregulated miR in the group with BCR and was
further investigated in the entire cohort by in situ hybridiza-
tion. Higher levels of MiR-21 associated with a worse BCR-free
survival in a subgroup analysis of patients with GS 6 and not
for patients with ≥7. In the entire cohort, there was only a
trend towards an association between miR-21 expression and
BCR (p = 0.089) [91]. In a study by Li et al., higher expression of
miR-21 was not significantly associated with a 5-year BCR-free
survival, but did predict a worse median OS [92]. This different
outcome, compared to that in Melbo-Jorgensen et al., can be
explained by a larger group of patients with GS ≥7 and using
only in situ hybridization (ISH) to quantify miRs, instead of ISH
and RT-PCR. MiR-221 was quantified by RT-PCR in two studies,
with lower levels of miR-221 detected in cancer compared to
BPH tissue, and higher levels in PCa associated with a shorter
time to cancer-related death [93,94]. Spahn et al. also found a
worse BCR-free survival in patients with lower levels of miR-
221 [94].
The MiQ score and the 3-miRNA prognostic classifier were
developed by Larne et al. and Kristensen et al., respectively. The
MiQ score consists of a ratio of MiR-96, MiR-183, MiR-145, and
MiR-221 and the 3-MiRNA prognostic classifier of MiR-185, MiR-
221, and MiR-326. These MiRs were selected from a larger MiR
panel in an initial training cohort, and these most discriminatory
MIRs were further validated in a separate cohort of patients
with PCa. Both tests could predict BCR-free survival [95,96].
Yang et al. compared the expression of miR-21 in peripheral
blood mononuclear cells (PBMCs) by RT-PCR in newly diagnosed
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patients with PCa. Elevated MiR-21 in PBMCs appeared to associ-
ate with a significantly shorter median survival time [97].
12. Circulating tumor cells
Circulating tumor cells (CTCs) can be detected in the peripheral
blood of PCa patients, even well before the occurrence of clinically
detectable metastases. Importantly, CTCs are heterogeneous and
may reflect polyclonality and clonal dominance during therapeu-
tic selection. CellSearch is the first and only US FDA-approved test
for the detection and enumeration of CTC in patients with metas-
tasized PCa. CellSearch detects CTCs expressing both Epithelial
Cell Adhesion Molecule (EpCAM) and cytokeratins 4, 5, 6, 8, 10, 13,
18, and 19 [98], with the disadvantage of not detecting CTCs
without this immunophenotype, such as EpCam-negative CTC
undergone epithelial-to-mesenchymal transition (EMT).
Molecular characterization of CTCs using DNA-based techniques
is feasible with the CellSearch system, and molecular alterations
such as ERG translocations, PTEN loss, and AR and MYC copy
number changes can be detected [99]. In addition, immunocyto-
logical studies have associated cellular localization of AR, or bund-
ling of microtubules, with response to treatment and drug–target
engagement. Other technologies for the quantitative and qualita-
tive assessment of CTCs include the Magsweeper, Verifast,
RosetteSep, Parsortix, and CellCollector [100]. The latter is an in
vivo assay that captures EpCAM-positive CTCs by an antibody-
coated needle in a vein. EPISPOT is an EpCAM-independent assay
that detects PCa cells based on their secretion of PSA [101,102].
The prognostic relevance of CTCs has been extensively investi-
gated in patients with CRPC, but due to few detectable CTCs in
patients in the HSPC setting, very few studies have been per-
formed in relation to outcome and with patients on AS.
12.1. Prognostic value of CTCs
In a study with 15 patients with locally advanced high-risk PCa,
the CellSearch platform was used to evaluate CTC presence in
relation to BCR-free survival [103]. CTC count was measured
before and after neoadjuvant chemotherapy or RP. There was
a trend for a better BCR-free survival in CTC negative (<1 CTC/
20 mL) patients. Three later studies using the CellSearch system
with CTCs/7.5 mL found no association between CTC presence
and BCR-free survival or progression of disease [104–106].
Theil et al. recently showed the ability of the CellCollector
platform to detect CTC, ex vivo on 15 mL of blood, of patients
with BPH, localized PCa, locally advanced PCa, and metasta-
sized PCa; this study was recenlty published and required prior
to the in vivo use of the antibody-coated wire in the veins of
PCa patients [102]. This CellCollector platform was able in
identifying cells defined as CTCs in 92.3% of all patients with
localized PCa with a mean of 4.6 CTCs. CTCs were also
detected in 32.5% of patients with BPH. There was a signifi-
cantly worse OS in patients with >5 CTC/7.5 mL compared to
patients with <5 CTC/7.5 mL (p = 0.035) [102]. With the
CellCollector platform, much higher detection rates of CTCs
were found compared to the CellSearch platform and other
studies in HSPC.
13. Cell-free DNA
Cell-free DNA (cfDNA) can be detected in the plasma of PCa
patients and comprises of a mixture of circulating cell-free
tumor DNA and cell-free nontumor DNA. The average tumor
content in PCa averages approximately 25% (with ranges
between 0.1% and 95%), with cell-free tumor DNA reported
to represent multiple tumor sites [107]. It contains coding
and noncoding DNA and is composed of short double-
stranded nucleosomal size DNA fragment (~170 bp). The
mechanisms by which cfDNA is released into the circulation
may include necrosis, apoptosis, and active secretion [108].
CfDNA can be isolated and quantified by column-based
isolation and subsequent detection using high-sensitivity
DNA dyes or by quantitative RT-PCR from both serum or
plasma [109]. CfDNA is amenable to qualitative, e.g. genetic
and epigenetic analyses of tumor DNA, and quantitative
analyses.
13.1. Prognostic value of cfDNA
Wroclawski et al. investigated in a prospective study the correla-
tion between the level of plasma cfDNA and BCR-free survival
[110]. They included 133 treatment-naive patients at following
histologically proven diagnosis of PCa. The mean follow-up was
13.5 months, but cfDNA levels were still of prognostic significance
with shorter BCR-free survival for patients with an increase in
cfDNA in the first evaluation after RP or hormone therapy and in
patients with at least one cfDNA value above 140 ng/mL during
follow-up. In contrast, in a retrospective study by Bastian et al., 192
patients with localized PCa, who underwent RP, were included to
investigate serum cfDNA levels as a prognostic biomarker by RT-
PCR. In this study, 29% of the patients experienced BCR with a
median time to PSA recurrence of 2 years. There was a significant
difference in cfDNA concentration at diagnosis between patients
with and without BCR in uni- and multivariate analyses [111]. Xia
et al. performed whole-genome and targeted NGS of cell-free
plasma DNA of 20 PCa patients, including 10 HSPC patients prior
and 4months after initiation of ADT. Prior to ADT, AR amplification
was detected in 1/10 and gain of the TMPRSS2 locus in 1/10, with
detectable loss of PTEN in 0/10 HSPC patients. Following ADT,
significantmutational changeswere detected in genes involved in
androgen biosynthesis and metabolism and AR activation. They
also were able to associate greater tumor DNA fraction in the
cfDNA with poorer OS when all 20 patients, combining the 10
HSPC and 10 CRPC patients, were analyzed collectively [112].
14. Conclusion
Our understanding and knowledge of PCa have improved
dramatically over the last 10 years, partly due to advances in
molecular characterization technologies and the systematic
and comprehensive exploration of the genetic and epigenetic
basis of human cancer. Advanced molecular tumor maps have
been created for primary PCa (that includes the TCGA data set)
and for CRPC (that includes the SU2C-PCF multi-institutional
mCRPC project), with these advances and insight now translat-
ing into biomarkers aiding clinicians in the early diagnosis of
PCa, as well as prognostication and patient stratification in
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those diagnoses with the disease, with novel predictive bio-
marker now being successfully developed in both disease
states. In this review, we focused on primary HSPC and pro-
vided a comprehensive overview of the available prognostic
and predictive tissue-based and noninvasive liquid biopsy
biomarkers (Table 1) and their incorporation into AS strategies
and during watchful waiting programs.
15. Expert commentary
The natural history of HSPC is highly variable, due to tumor
heterogeneity of primary PCa and subclonal expansion during
therapeutic selection pressure and progression to lethality [113].
Therefore, current nomograms, consisting of clinicopathological
characteristics at diagnosis, such as PSA level, PSA kinetics, GS,
and Tumor, node andmetastasis (TNM) grading, can only predict
PCa-specific mortality on population basis. In the era of persona-
lized medicine, incorporation of common molecular aberrations
in prognostic nomograms will individualize and improve out-
come prediction; more importantly, these specific aberrations
may be used to stratify patients for active treatment regimens,
such as RP or definitive radiotherapy, or for watchful waiting
programs. Specific molecular aberrations can be detected in
the peripheral blood months prior to BCR or radiological pro-
gression, and early detection may lead to future improvements
in outcome of patients involved in AS programs.
Whole-exome and genome sequencing data indicate that
increasing genomic alterations (genomic amplification, deletion,
and polyploidy) and nonsynonymousmutations correlatewith the
five increasing PGGs proposed by Epstein and colleagues in 2013
[7,114]. These genomic correlates may improve prognostic discri-
mination when combined with clinical prognostic nomograms,
such as the National Comprehensive Cancer Network classification
system and the Stephenson nomogram [115]. Indeed, overall
SCNA burden alone is associated with BCR and disease-specific
death in patients followed after RP. The most common aberration
in primary PCa is the gene fusion between the androgen-regu-
lated gene TMPRSS2 and the ETS family member ERG. Large
studies and a meta-analysis have not identified an unequivocal
relationship between presence of the fusion transcript TMPRSS2–
ERG and BCR or mortality, which may imply that ETS fusion
transcripts are early clonal drivers most important in the transition
of prostate tissue into Prostatic Intraepithelial Neoplasia (PIN) and
prostate adenocarcinoma. Levels of the fusion transcript or ERG
expression do appear to associate with a worse outcome in
primary HSPC and appear independent of AR transcriptional activ-
ity [3]. No predictive role has been established for ETS-fusion status
in HSPC, nor in the castration-resistant setting for treatment with
abiraterone [116]. Surprisingly, ERG appears to play a role as a
microtubule-associated protein affecting microtubule dynamics
and interfering with drug–target engagement of taxanes with
tubulin; in PCa patients, TMPRSS2–ERG copy number was asso-
ciated with a lower likelihood of biochemical response to doce-
taxel chemotherapy [117,118]. Non-ERG-driven PCa is a distinct
molecular subtype compared to ETS-driven PCa; non-ERG/non-
ETS PCa associates with SPINK overexpression, loss of the chroma-
tin-remodeling enzyme chromodomain-helicase-DNA-binding
protein 1 (CHD1), and moderately elevated DNA methylation
patterns [3,11]. The molecular taxonomy of primary PCa revealed
four distinct molecular subtypes based on ETS-family fusion status
and four groups based on presence of SPOP, FOXA, IDH1, and
other molecular aberrations. Decipher-generated RNA microarray
expression data from >1500 primary PCa patients did not identify
differences in outcome between patients harboring ERG-positive
and ETS-positive gene rearrangements or between those with
non-ERG/non-ETS patients with SPINK alterations [119]. Other
genomic clusters of primary PCa may show more prognostic or
predictive utility. Abundant translational data have been acquired
on the prognostic utility of the tumor suppressor gene PTEN and
the oncogene MYC; PTEN loss and MYC gain are one of the most
commonly identified SNCAs and are both associated with an
increased risk of BCR and disease-specific death. The combination
of both genomic events increases the risk of a poor outcome, as
well as for the combination of PTEN loss and ERG expression.
There is an inconsistency in studies evaluating PI3K pathway
activation, partially explained by variation in the detection of
homozygous versus heterozygous loss, assessment of loss-of-func-
tion mutation status, and variations in cohort composition. PTEN
status in CRPC correlates well to HSPC and associates with a
shorter median OS and a shorter median duration of response to
abiraterone treatment, with preclinical results suggesting PI3K/Akt
activation in regulating AR transcriptional output and overcoming
resistance to androgen-directed therapy [120]. Ipasertib, an oral
ATP-competitive inhibitor of Akt, improved radiographic PFS
when combined with abiraterone in CRPC patients with PTEN
loss [121]. These results underscore PI3K/Akt activation as a puta-
tive driver of resistance of ADT also in the HSPC setting, with
prospective randomized studies with agents targeting the PI3K
pathway in the primary setting eagerly awaited. If there is a
unifying inability to repair DNA breaks, then an opportunity for
rational therapy design may exist. Although separate studies
[122,123] have associated inter- and intrachromosomal structural
rearrangements (chromothripsis/chromoplexy) with aworse prog-
nosis in other tumor types, the clinical implications in PCa are not
clear and should be addressed in future studies. This also applies
to the prognostic role of chromatin-remodeling aberrations, such
as CHD1-deleted tumors. Also, loss of PTEN has been associated
with chromatin decondensation and an open structure of active
chromatin [124]. Recent studies however implicate a predictive
role for CHD1 loss, as translational studies suggest that patients
harboring these deletions may susceptible for PARP inhibitors due
to aberrant DNA repair. This could lead to the identification and
stratification of patients with ETS-negative CHD1 loss/SPOP-
mutant PCa for agents targeting DNA repair.
AR alterations are infrequent in treatment-naive primary
PCa; however, augmented AR signaling does affect prognosis
aversely. Whereas AR-Vs, like AR-V7, are strongly overexpressed
in patients with CRPC and associates with primary and
acquired resistance to androgen-directed therapy, the pre-
sence and utility of AR-Vs in HSPC show conflicting results
and the need for further prospective evaluation [3,65]. There
is an inverse correlation between AR expression/signaling and
prognosis, i.e. lack of AR expression, albeit rare, is typical for
small-cell carcinoma of the prostate. This is an aggressive
variant of the disease, subclonally present in high GS primary
cancers and/or resulting following selection pressure of multi-
ple lines of androgen-directed therapy in latter CRPC stages
[125]. Defects in DNA repair genes are present in a small subset
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of patients with primary localized PCa. While the predictive
value of these somatic and germ line aberrations is well under-
stood in patients with mCRPC [64,72,73], the prognostic utility
has defined by retrospective analyses of clinicopathological
characteristics at primary diagnosis. Patients with homologous
recombination defects, particularly of BRCA2, have more
aggressive disease features and show worse OS from diagno-
sis. Molecular characterization of patients with high-grade dis-
ease and/or presence of metastatic disease at diagnosis may
identify germ line and somatic carriers early and could improve
outcome when these patients are treated with combinatory
regimens including platinum-based chemotherapy or PARP
inhibitors in neoadjuvant strategies, adjuvant therapies, or
combinatory regimens with ADT. Other promising molecular
tools include the Oncotype DX GPS, the Decipher test, and the
CCP Score (Prolaris), with no results from prospective studies to
confirm the prognostic value of these multigene expression
classifiers. Epigenetic alterations are changes of gene expres-
sion including CpG methylation, histone modification, gene
imprinting, and miRs. APC and GSTP1 are probably the most
investigated hypermethylated genes in the promoter region.
Hypermethylation of APC is associated with BCR and a worse
DSS. Genome-wide methylation studies will provide more
insight on the prognostic and predictive features of (promoter)
hypermethylation in HSPC. In the MiR, profiles carry tumor-
specific information such as Gleason-stage, AR activity, and
metastatic potential and show independent prognostic value
in relation to biochemical recurrence and survival. Only limited
direct targets of MiRs have been validated and include genes
involved in the regulation of CCP, EMT, and PI3K pathway
activation [85,86]. Further insight in MiR expression in low-
and high-risk cancers, their direct targets, and the develop-
ment of novel therapeutic strategies that can reintroduce MiRs
with tumor suppressor function or alter MiRs that function as
oncoMiRs, is now warranted. CTCs are infrequently found in
patients with localized PCa, limiting the clinical utility of CTC
quantification and qualitative assessment with platforms that
utilize small volumes of blood. This obstacle may be overcome
by using leukapheresis product with CellSearch or other plat-
forms to increase the yield of enriched CTCs; alternative assay
could involve the use of an antibody-coated wire to directly
capture CTCs from large blood volumes. Quantitative assess-
ment of plasma or serum cfDNA levels appears of prognostic
value in patients with low-risk HSPC. However, considering the
noninvasive method, future research should focus on qualita-
tive NGS studies on cfDNA in low-risk patients for reclassifica-
tion purposes or on the detection of specific genomic
aberrations in patients in AS programs. Many more transla-
tional studies have been performed in the castration-resistant
state, where serial cfDNA plasma analyses have identified rapid
adaption to anticancer therapy, indicating that genomic
changes may occur rapidly, and should be monitored in liquid
biopsy monitoring programs in the academic setting.
16. Five-year view
Considering the high frequency of ETS-gene fusion status, pro-
spective studies detecting TMPSRSS2-ERG transcripts would be
helpful in the detection of early recurrence during AS.
TMPRSS2–ERG expression does not appear to predict response
to ADT in patients with HSPC [126,127]; however, translational
studies on TMPRSS2–ERG status, expression level, and outcome
to upfront docetaxel in patients with metastatic HSPC, recruited
to CHAARTED [128] and the M+ STAMPEDE cohort [129], are
awaited due reports on the interaction between ERG and micro-
tubule–taxane interaction and taxane responsiveness [118].
Whole-genome and exome sequencing reveals genomically
distinct subtypes, of which subtypes may be molecularly bar-
coded by ETS/SPINK1/SPOP/CHD1/RAS-RAF/PTEN/TP53 status
[1], that also should include SCNA burden; prospective studies
utilizing this molecular barcode in the primary setting will
potentially identify molecular subtypes with adverse prognosis
following RP, radical radiotherapy, or in watchful waiting
cohorts. Trials targeting the PI3K pathway in conjunction with
ADT that may include ipasertib or AZD5363 among others are
eagerly awaited in patients with PTEN aberrations, such as
deletion (truncating), mutations, or those causing loss-of-func-
tion, or epigenetic or posttranscription regulation by MiRs tar-
geting this pathway, and may include other components
PIK3CA, PIK3CB, and Akt itself. The oncogene MYC associated
strongly with poor disease-specific mortality in most studies in
HSPC; MYC might be targeted by bromodomain extraterminal
enhancer (BET) inhibitors, as MYC function is partially mediated
by BET proteins, and preclinical studies with BET inhibitors show
a decrease in MYC expression associating with inhibition of PCa
cell growth [130,131]. Future prospective studies in patients
with localized PCa must show the safety and efficacy of agents
targeting MYC in patients with MYC-driven cancers. To increase
the specificity of a biomarker suite in primary PCa, all miR target
genes need to be identified, and prospective pathway-driven
translational studies need to be undertaken. The role to predict
therapeutic efficacy of androgen-directed agents using AR-V
expression was first demonstrated in CRPC with the constitu-
tively active AR-V7 variant-predicted therapy response to abir-
aterone acetate and enzalutamide. This finding could have
significant impact on therapy decisions, and standardized tests
(CLIA/FDA IVD) are currently being evaluated; however, this is
probably not of importance in treatment-naive HSPC where AR-
V7 has low or absent expression. However, we believe that
agents targeting alternative splicing of full-length AR may be
of clinical utility in patients with high-grade cancers in conjunc-
tion with ADT. The predictive role of homologous recombina-
tion defects is comprehensively being studied in trials with
PARP inhibitors and platinum regimens in the castration-resis-
tant state, due to enrichment of germ line aberrations and
accumulation of somatic defects in up to 20–30% in the latter
stages of the disease. Extrapolation of olaparib efficacy seen in
the TOPARP-A trial suggests a role for these therapies in
patients with localized PCa harboring DNA repair defects.
There is clear utility for implementing CTC enumeration in the
hormone-sensitive setting, albeit using platforms that can han-
dle larger quantity of blood volumes, and particularly could be
useful in detecting early relapse or switch to a metastatic
potential by noninvasive serial assessments in patients in sur-
veillance programs. Lastly, many studies on molecular markers
in HSPC used BCR as end point; PSA recurrence is a poor
surrogate for disease progression or PCa-specific mortality
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[132], and future studies should incorporate metastasis-free
survival, which may be used as a surrogate for OS [133].
Key issues
● Insight in the molecular changes involving key signaling
pathways in primary PCa has undergone major advances
through the rapid innovation and implementation of tumor
profiling technologies.
● AS is accepted as a valuable strategy to prevent over-diag-
nosis and over-treatment, however the selection criteria for
those to receive AS have still to be optimized and the early
detection of transformation of indolent into lethal PCa has
to be improved by implementing molecular markers.
● Molecular abnormalities may be used as clinical tools to
assess prognosis and improve early detection of residual
disease in patients with high risk localized primary PCa
recruited to active surveillance programs.
● The most common aberration in primary PCa is presence of
the TMPRSS2-ERG fusion gene, without unequivocal rela-
tionship with presence of the fusion gene and BCR or
mortality. The level of the transcript, however, may be
associated with a worse outcome in primary HSPC.
● PTEN loss and MYC gain are one of the most commonly
identified SCNAs and are both associated with an increased
risk of BCR and disease-specific death.
● Intrachromosomal structural variation (chromothripsy) and
interchromosomal variants (chromoplexy) can commonly
be detected in HSPC, with qualitative evaluation likely pro-
viding insight in intra-patient drivers of progression.
● Transcriptional activity and extent of DSB repair is regulated
by genes involved in chromatin regulation, and include
CHD1. The literature shows conflicting results on the prog-
nostic impact of CHD1 deletions, however recent evidence
suggests benefit of PARP-inhibitors in these patients.
● Whereas AR splice variants, like AR-V7, are strongly over
expressed in patients with CRPC and associates with pri-
mary and acquired resistance to androgen-directed therapy,
the presence and utility of AR-Vs in HSPC show conflicting
results and the need for further prospective evaluation.
● Defects in DNA repair genes are present in a small subset
of patients with primary localized PCa, with enrichment of
homologous recombination defects in patients with more
aggressive disease features and in those that develop
CRPC.
● Epigenetic alterations include DNA hypermethylation and
miRs. Whereas DNA hypermethylation is a promising
prognostic marker, only limited direct targets of MiRs
have been validated including genes involved in the
regulation of cell-cycle progression, EMT, and PI3K path-
way activation
● CTCs are infrequently found in patients with localized PCa
limiting the clinical utility of CTC quantification and quali-
tative assessment in assays utilizing low blood volumes
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